学术
国际标准刊号：ISSN 1673-422X
国内统一刊号：CN 37-1439
摘 要:
热休克蛋白．抗原肽复合物（HSPPC）被称为个体化肿瘤疫苗。临床研究显示HSPPC用于肿瘤患者免疫接种是安全可行的，它能触发部分患者强有力的抗肿瘤免疫排斥反应，并产生一定临床效果。研究发现临床效果与免疫学反应间有一定相关性，且不良反应轻微，未观察到自身免疫现象。[著者文摘]
文章出处:
《国际肿瘤学杂志》-2007年34卷6期 -411-413页
Journal of International Oncology
栏目信息:
分 类 号:
文献标识码:
A
文章编号:
1673-422X（2007）06-0411-03
Clinical researches on heat shock protein-peptide complex vaccines for cancer
YIN Jun-jie. Department of Hematology, Fu-xing Hospital, Capital University of Medical Sciences, Belling 100038, China
Abstract:
The heat shock protein-peptide complex （HSPPC） is recognized as a personalized tumor vaccine. Some clinical trials completed in certain tumors show the vaccination with autologous tumor-derived HSPPC is a feasible and safe approach, and able to induce an strong antitumor response in a percentage of patients associated with clinical benefits. Clinical benefits are related with the antitumor response. No obvious toxicity and autoimmunity diseases related with the vaccination are observed.[著者文摘]
Key words:
Heat shock proteins; Cancer vaccine; Biotherapy
收稿日期: 2007-01-15
更多评论>>文章评论
更多>>免费文章
cqvip.com